Peter Oppenheimer, Goldman Sachs chief global equity strategist, joins 'Money Movers' to discuss the expected economic ...
Oppenheimer downgraded Nice (NICE) to Perform from Outperform without a price target The company’s organic cloud growth continues to ...
The Rock's filmography has been tough sledding in recent years and his latest Christmas-themed project seems to be more of ...
Greece’s Thessaloniki Film Festival ends this evening with a screening of The End, the latest feature project from the ...
The Rock can always put a wildly positive spin on any of his movies, but his latest promotional clip takes the cake: he’s ...
Oppenheimer analyst Rick Schafer raised the firm’s price target on Nvidia (NVDA) to $175 from $150 and keeps an Outperform rating on the ...
Oppenheimer's Limited-Edition Steelbook releases November 19 and comes with 4K and standard Blu-ray discs as well as a ...
Investing.com -- Oppenheimer analysts initiated coverage on five key storage and infrastructure stocks on Wednesday, offering insights into their growth potential within the industry. Rubrik was ...
In a report released today, Francois Brisebois from Oppenheimer maintained a Hold rating on Ovid Therapeutics (OVID – Research Report).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback